Last updated: February 13, 2026
What is NDC 42291-0132?
NDC 42291-0132 refers to a specific drug product registered under the National Drug Code system. According to available records, this NDC corresponds to Ubrogepant (Ubrelvy), a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in late 2019 for acute treatment of migraine [1].
Market Size and Growth Drivers
Market Context
The global migraine market, driven by increasing prevalence and awareness, is projected to reach approximately USD 4.2 billion by 2027, growing at a compound annual growth rate (CAGR) of 3.7% between 2020 and 2027 [2].
Key Market Drivers
-
Increasing migraine prevalence: An estimated 1 billion people experience migraines worldwide [3].
-
Limited existing treatments: Traditional therapies (NSAIDs, triptans) have limitations due to contraindications and side effects, boosting demand for newer options like ubrogepant.
-
FDA approval of ubrogepant: Helps expand market share for CGRP antagonists, including competitors like rimegepant and erenumab.
-
Pricing and reimbursement policies: Will influence adoption rates, especially under Medicare and private insurers.
Competitive Landscape
Main competitors include:
-
Rimegepant (Nurtec ODT): Approved since 2019 for migraine treatment, with a broader indication for both acute and preventive therapy.
-
Erenumab (Aimovig): An injectable CGRP antagonist for preventive migraine treatment.
-
Topiramate and propranolol: Preventive medications with generic options.
Pricing and Reimbursement
Historical Pricing Data
-
Ubrogepant (Ubrelvy): List price approximately USD 850 for a 30-count, 50 mg tablets, equating to about USD 28.33 per tablet [4].
-
Insurance coverage: Insurers may negotiate discounts, and manufacturer assistance programs are common.
Pricing Trends
- Since FDA approval, the list price has remained relatively stable, though discounts and patient assistance programs reduce out-of-pocket costs.
- Competitive pricing has shifted slightly downward in response to biosimilars and generics for other migraine medications.
Market Projections and Price Trends
| Year |
Estimated Market Size (USD Billion) |
Expected Price Range (USD per 30 tablets) |
Key Factors Influencing Prices |
| 2023 |
0.2 |
850 (list), effective price ~ USD 600-700 |
Increased adoption, insurance negotiations |
| 2025 |
0.5 |
800-900 |
Growing prescribing patterns, competitive effects |
| 2027 |
1.0 |
750-850 |
Entry of biosimilars, expanded indications |
Regulatory and Patent Outlook
- Patent protections: Likely until 2030, with patent filings covering formulation and uses [5].
- Potential biosimilar entry: Not yet approved; biosimilar competition unlikely soon but could influence pricing later in the decade.
Implications for Stakeholders
- Pharmaceutical companies: Opportunities for launching generics or biosimilars after patent expiry.
- Investors: Growth potential remains high, but price pressures and competition may impact margins.
- Providers: Preference will shift toward cost-effective, reimbursable options.
Key Takeaways
- NDC 42291-0132 (Ubrogepant) operates in a growing migraine market with expanding indications.
- Pricing remains high but stable, with effective prices after discounts likely around USD 600-700 per month.
- Growth will depend on insurance reimbursement, competing therapies, and new product entries.
- Patent protections and potential biosimilar competition could influence prices after 2029.
- Market expansion strategies should focus on increasing awareness and formulary inclusion.
FAQs
Q1: How does ubrogepant compare to other CGRP therapies?
A: Ubrogepant is an oral medication, offering faster, non-injectable treatment, differentiating it from injectable CGRP antagonists like erenumab.
Q2: What are the primary factors influencing the drug’s price?
A: Reimbursement policies, competition from generics, insurance negotiations, and market adoption rates.
Q3: When can biosimilars or generics be expected?
A: Patent expiration is projected around 2030; biosimilar development may begin 5-7 years earlier.
Q4: Are there significant off-label uses?
A: No, ubrogepant's approval is specific to acute migraine treatment; off-label use is limited.
Q5: How does market growth vary geographically?
A: The US dominates due to high migraine prevalence and payer coverage; Europe and Asia-Pacific show increasing adoption trends.
References
[1] FDA. (2019). FDA approval of Ubrelvy.
[2] Grand View Research. (2022). Migraine therapeutics market analysis.
[3] Global Burden of Disease Study. (2019). Migraine prevalence data.
[4] GoodRx. (2023). Ubrelvy pricing.
[5] PatentScope. (2022). Ubrogepant patent filings.
